Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 13/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843547 | 0.89 | NT5E (0.75) | NT5EADORA3DNPH1P2RX3P2RX2 | |
| SCHEMBL22843528 | 0.89 | NT5E (0.57) | NT5EDNPH1PLCG1ENPP1 | |
| SCHEMBL22843551 | 0.88 | NT5E (0.64) | NT5EDNPH1P2RX3P2RX2 | |
| SCHEMBL22843492 | 0.86 | NT5E (0.68) | NT5EDNPH1P2RX3P2RX2 | |
| SCHEMBL19100912 | 0.86 | NT5E (0.80) | NT5EADORA3DNPH1PLCG1ENPP1 | |
| SCHEMBL22843548 | 0.86 | NT5E (0.61) | NT5EDNPH1P2RX3P2RX2 | |
| SCHEMBL22843614 | 0.86 | NT5E (0.61) | NT5EADORA3DNPH1ADORA1P2RX3 | |
| SCHEMBL22843641 | 0.81 | NT5E (0.86) | NT5E | |
| SCHEMBL22843635 | 0.78 | NT5E (0.74) | NT5E | |
| SCHEMBL22843631 | 0.78 | NT5E (0.76) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | NT5E 10/4885ADORA3 19/4885DNPH1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.